Company attributes
Other attributes
TC BioPharm is a biotechnology company developing cell therapies for treating cancer and severe viral infections that is headquartered in Glasgow, Scotland and was founded in 2013 by Angela Scott, Artin Moussavi, David Gallagher, and Michael Leek.
In addition to treating cancer the company looks to treat a range of disorders that are brought on by viral infections. They have developed the product ImmuniCell, which is being tested in clinical studies to fight against renal cell carcinoma, non-small cell lung cancer and melanoma patients.
In the long run the company is interested in developing and commercializing their cell-based products and solutions in order to treat diseases across a broad range of patients. They have developed allogenic CAR-T cell therapy products for the purpose of treating cancer, and are developing gamma delta T-cell therapies to fight against infectious diseases.
Gamma Delta T-cells (DGT cells) are a component of white blood cells and are responsible for innate immune system responses. They monitor the body's signs of biological stress and are among the first response options the body has. TC BioPharm looks to utilize the traits of a DGT cell to provide therapeutics that treat diseases and specifically cancer.
